Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Market Research Report present a detailed analysis of the market listing Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology, Drug therapies and pipeline for study period from 2018-2030.

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Market Size & Share | Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Market Research Report, Market Analys...

1. Key Insights

2. Report Introduction

3. Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Market Overview at a Glance

3.1. Market Share (%) of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) by Therapies in 2018

3.2. Market Share (%) of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) by Therapies in 2030

4. Future Prospects

5. Executive Summary of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)

6. Key Events

7. Systemic Sclerosis-associated Interstitial Lung Disease: Disease Background and Overview

7.1. Introduction

7.2. Signs and Symptoms

7.3. Risk Factors

7.4. Causes

7.5. Pathogenesis

7.6. Diagnostic Approach

7.6.1. Diagnostic algorithm

7.6.2. Diagnostic Recommendations

7.6.3. Biomarkers in Systemic Sclerosis-associated Interstitial Lung Disease

7.7. Treatment and Management

7.7.1. Treatment Algorithm

7.7.2. Treatment Recommendations

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Methodology

8.3. Assumptions and Rationale: 7MM

8.4. Total Prevalent Cases of SSc in the 7MM

8.5. Diagnosed Prevalent Cases of SSc in the 7MM

8.6. Total Prevalent Cases of SSc-ILD in the 7MM

8.7. Diagnosed Prevalent Cases of SSc-ILD in the 7MM

8.8. The United States

8.8.1. Total Prevalence of Systemic Sclerosis (SSc) in the United States

8.8.2. Total Diagnosed Prevalence of SSc in the United States

8.8.3. Total Prevalence of SSc-ILD in the United States

8.8.4. Total Diagnosed Prevalence of SSc-ILD in the United States

8.8.5. Gender-specific Diagnosed Prevalence of SSc-ILD in the United States

8.8.6. Age-specific Diagnosed Prevalence of SSc-ILD in the United States

8.8.7. Severity-specific Prevalence of SSc-ILD in the US

8.9. EU5

8.9.1. Total Prevalence of Systemic Sclerosis (SSc) in EU-5

8.9.2. Total Diagnosed Prevalence of SSc in EU-5

8.9.3. Total Prevalence of SSc-ILD in EU-5

8.9.4. Total Diagnosed Prevalence of SSc-ILD in EU-5

8.9.5. Gender-specific Diagnosed Prevalence of SSc-ILD in EU-5

8.9.6. Age-specific Diagnosed Prevalence of SSc-ILD in EU-5

8.9.7. Severity-specific Prevalence of SSc-ILD in the EU5

8.10. Japan

8.10.1. Total Prevalence of SSc in Japan

8.10.2. Total Diagnosed Prevalence of SSc in Japan

8.10.3. Total Prevalence of SSc-ILD in Japan

8.10.4. Total Diagnosed Prevalence of SSc-ILD in Japan

8.10.5. Gender-specific Diagnosed Prevalence of SSc-ILD in Japan

8.10.6. Age-specific Diagnosed Prevalence of SSc-ILD in Japan

8.10.7. Severity-specific Prevalence of SSc-ILD in Japan

9. Patient Journey

10. Marketed Therapies

10.1. Key Cross Competition

10.2. Ofev (Nintedanib Capsules): Boehringer Ingelheim Pharmaceuticals

10.2.1. Drug Description

10.2.2. Regulatory Milestones

10.2.3. Other Development Activities

10.2.4. Clinical Development

10.2.5. Clinical Trials Information

10.2.6. Safety and Efficacy

10.2.7. Product Profile

10.3. Actemra/RoActemra (Tocilizumab): Roche

10.3.1. Drug Description

10.3.2. Regulatory Milestones

10.3.3. Other Development Activities

10.3.4. Clinical Development

10.3.5. Clinical Trials Information

10.3.6. Safety and Efficacy

10.3.7. Product Profile

11. Emerging Therapies

11.1. Key Cross Competition

11.2. ACE-1334: Acceleron Pharma

11.2.1. Drug Description

11.2.2. Other Developmental Activities

11.2.3. Clinical Development

11.2.4. Clinical Trials Information

11.2.5. Product Profile

11.3. FCR001: Talaris Therapeutics

11.3.1. Drug Description

11.3.2. Other Developmental Activities

11.3.3. Clinical Development

11.3.4. Clinical Trials Information

11.3.5. Product Profile

11.4. Belumosudil (KD025): Kadmon Corporation

11.4.1. Drug Description

11.4.2. Other Developmental Activities

11.4.3. Clinical Development

11.4.4. Clinical Trials Information

11.4.5. Product Profile

12. SSc-ILD: Seven Major Market Analysis

12.1. Key Findings

12.2. Market Methodology

12.3. Market Outlook

12.4. Potential of Emerging Therapies of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)

12.5. Key Market Forecast Assumptions

12.6. Market size of SSc-ILD in the 7MM

12.7. Market size of SSc-ILD by Therapies in the 7MM

12.8. Market size of SSc-ILD in the United States

12.8.1. Total Market size of SSc-ILD in the United States

12.8.2. Market Size by Therapies in the US

12.9. Market size of SSc-ILD in EU-5

12.9.1. Total Market size of SSc-ILD in EU5

12.9.2. Market Size of SSc-ILD in EU5 by Therapies

12.10. Market size of SSc-ILD in Japan

12.10.1. Total Market size of SSc-ILD in Japan

12.10.2. Market Size by Therapies in Japan

13. KOL Views

14. Market Drivers

15. Market Barriers

16. SWOT Analysis

17. Unmet Needs

18. Market Access and Reimbursement

18.1. United States

18.2. Europe

18.3. Japan

19. Appendix

19.1. Report Methodology

19.2. Bibliography

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)- Market Insight, Epidemiology and Market Forecast -2030

DelveInsight' s Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Market Insights, Epidemiology and Market Forecast - 2030 report provides  the detailed overview..

Customize Reports As Per Your Needs